Document is current
Any future updates will be listed below
-
Authors
Gandhi, Shipra
Opyrchal, Mateusz
Ford, Cayla
Fitzpatrick, Victoria
Grimm, Melissa
Basse, Per
Quinn, Marie
Witkiewicz, Agnieszka
Attwood, Kristopher
Ernstoff, Marc
O’Connor, Tracey
Early, Amy
Levine, Ellis
Kalinski, Pawel
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04081389 at ClinicalTrials.govDocuments that mention this clinical trial
Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy
https://doi.org/10.1136/jitc-2024-010960
Synergy between TLR3-ligand and IFN-α in the transient sensitization of “Cold” tumors to PD-1 blockade and the induction of systemic immunity
https://doi.org/10.1136/jitc-2025-012307
547 Safety and efficacy of de-escalated neoadjuvant chemoimmunotherapy of triple negative breast cancer (TNBC) using chemokine-modulating regimen (rintatolimod, IFN-α2b, celecoxib)
https://doi.org/10.1136/jitc-2022-sitc2022.0547
321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer
https://doi.org/10.1136/jitc-2020-sitc2020.0321
Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer
https://doi.org/10.1136/jitc-2024-010058
- License Information
